Temporal changes of EGFR mutations and T790M levels in tumour and plasma DNA following AZD9291 treatment

PL Chia; H Do; A Morey; P Mitchell; A Dobrovic; T John

Journal article

Temporal changes of EGFR mutations and T790M levels in tumour and plasma DNA following AZD9291 treatment

PL Chia, H Do, A Morey, P Mitchell, A Dobrovic, T John

Lung Cancer | ELSEVIER IRELAND LTD | Published : 2016

DOI: 10.1016/j.lungcan.2016.05.003

Abstract

AZD9291, a T790M specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), has demonstrated impressive response rates in tumours harbouring the EGFR T790M resistance mutation. Emergence of resistance to AZD9291 has been shown to occur through several different mechanisms including the development of new mutations (e.g. C797S) in the EGFR tyrosine kinase domain. We studied two patients with paired tumour biopsies and blood samples pre- and post-progression on AZD9291 to explore possible resistance mechanisms.Pre- and Post-AZD9291 tumour biopsies as well as serial plasma samples were collected from two patients on the AURA clinical study (AZD9291 First Time in Patients ..

View full abstract

University of Melbourne Researchers

Tom John Author

Grants

Funding Acknowledgements

Thomas John received a NHMRC Early Career Fellowship. Puey Ling Chia received International Association for the Study of Lung Cancer (IASLC) Fellowship Award and The University of Melbourne, Australian Postgraduate Award. Alexander Dobrovic received funding from Cancer Australia. The Olivia Newton-John Cancer Research Institute is supported by a Victorian Government Operational and Infrastructure Support Grant.